-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to a study presented at a virtual meeting of the American Academy of Gastroenterology (ACG) in 2020, Vedolizumab is superior to Invlisy monotherapy in treating diarrhea and colitis associated with immunosupger inhibitors.
"Our first large-scale study showed that Vedolizumab had the same effect on the clinical remission of immunotherapy-mediated diarrhea and colitis compared to Invlizumab, but patients had significantly shorter courses and lower recurrence rates," said Dr. Yinghong Wang of the University of Texas Anderson Cancer Center.
the study included 150 patients with cancer immunotherapy (with a medium age of 64), of whom genitourinary cancers and melanomas were the most common.
patients with diarrhea and colitis as a result of being treated with checkpoint inhibitors.
only 61 cases received Vedolizumab treatment, 71 cases received inflixi monoantigen therapy and 18 cases received both drugs.
results showed that patients who received Vedolizumab alone received significantly shorter steroid treatment (35 days vs. 50 days, P-0.025) compared to patients who received only Invlizumab.
